GlaxoSmithKline news from FierceBiotech
NewsMerck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
FDA delays Entereg decision
GlaxoSmithKline and Adolor's seemingly never-ending effort to win approval for Entereg has hit yet another delay. The FDA informed the companies that it would not make a decision by Saturday, the Read more...
Traditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Report: GSK to fund venture firm, back start-ups
In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from Read more...
SPOTLIGHT: Epix wins $7.5M milestone
Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...
ALSO NOTED: ISTA announces positive data; Proteolix launches Phase II trial; and much more...
> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit Read more...
ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...
> Following a series of major setbacks trying to develop a vaccine for AIDS, pessimistic researchers say they're years away from success. Read more...
SPOTLIGHT: Glaxo appraises Sirtris' potential
A somewhat skeptical Matthew Herper at Forbes did a Q&A with Glaxo's Patrick Vallance on the big news that it's Read more...
GSK buys Sirtris for $720M
GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company--an 84 percent premium to Sirtris's closing price Tuesday. Read more...
| Press ReleasesGlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... PRESS RELEASE: GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breas GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases Data on abstract 6076 embargoed until Sunday 16 December Read more... PRESS RELEASE: GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay PHILADELPHIA, Dec. 17 -- GlaxoSmithKline announced today that it has received a complete response letter Read more... |
Get more GlaxoSmithKline coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight